Las_cifras_del_Cancer_en_Espana_2023.pdf. https://seom.org/images/Las_cifras_del_Cancer_en_Espana_2023.pdf
Posdzich P, Darr C, Hilser T, Wahl M, Herrmann K, Hadaschik B, et al. Metastatic Prostate Cancer—A Review of Current Treatment Options and Promising New Approaches. Cancers. 11 de enero de 2023;15(2):461.
Parker C, Castro E, Fizazi K, Heidenreich A, Ost P, Procopio G, et al. Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology. septiembre de 2020;31(9):1119-34.
James ND, Ingleby FC, Clarke NW, Amos CL, Attard G, Brawley CD, et al. Docetaxel for Nonmetastatic Prostate Cancer: Long-Term Survival Outcomes in the STAMPEDE Randomized Controlled Trial. JNCI Cancer Spectr. 25 de julio de 2022;6(4):pkac043.
Attard G, Murphy L, Clarke NW, Cross W, Jones RJ, Parker CC, et al. Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol. The Lancet. enero de 2022;399(10323):447-60.
Fizazi K, Gillessen S. Updated treatment recommendations for prostate cancer from the ESMO Clinical Practice Guideline considering treatment intensification and use of novel systemic agents. Annals of Oncology. junio de 2023;34(6):557-63.
Simon NI, Parker C, Hope TA, Paller CJ. Best Approaches and Updates for Prostate Cancer Biochemical Recurrence. American Society of Clinical Oncology Educational Book. julio de 2022;(42):352-9.
DOI: 10.1200/EDBK_351033
Parker CC, Clarke N, Cook A, Catton C, Cross WR, Kynaston H, et al. LBA9 Duration of androgen deprivation therapy (ADT) with post-operative radiotherapy (RT) for prostate cancer: First results of the RADICALS-HD trial (ISRCTN40814031). Annals of Oncology. 1 de septiembre de 2022;33:S1427.
DOI: 10.1016/j.annonc.2022.08.064
Van Den Broeck T, Van Den Bergh RCN, Arfi N, Gross T, Moris L, Briers E, et al. Prognostic Value of Biochemical Recurrence Following Treatment with Curative Intent for Prostate Cancer: A Systematic Review. European Urology. junio de 2019;75(6):967-87.
Freedland SJ, De Almeida Luz M, De Giorgi U, Gleave M, Gotto GT, Pieczonka CM, et al. Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer. N Engl J Med. 19 de octubre de 2023;389(16):1453-65.
Smith MR, Hussain MHA, Saad F, Fizazi K, Sternberg CN, Crawford ED, et al. Overall survival with darolutamide versus placebo in combination with androgen-deprivation therapy and docetaxel for metastatic hormone-sensitive prostate cancer in the phase 3 ARASENS trial. JCO. 20 de febrero de 2022;40(6_suppl):13-13.
DOI: 10.1200/JCO.2022.40.6_suppl.013
Hussain M, Tombal B, Saad F, Fizazi K, Sternberg CN, Crawford ED, et al. Darolutamide Plus Androgen-Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer by Disease Volume and Risk Subgroups in the Phase III ARASENS Trial. JCO. 10 de julio de 2023;41(20):3595-607.
Fizazi K, Foulon S, Carles J, Roubaud G, McDermott R, Fléchon A, et al. Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design. The Lancet. abril de 2022;399(10336):1695-707.
Wala J, Nguyen P, Pomerantz M. Early Treatment Intensification in Metastatic Hormone-Sensitive Prostate Cancer. JCO. 10 de julio de 2023;41(20):3584-90.
Pozas J, Álvarez Rodríguez S, Fernández VA, Burgos J, Santoni M, Manneh Kopp R, et al. Androgen Receptor Signaling Inhibition in Advanced Castration Resistance Prostate Cancer: What Is Expected for the Near Future? Cancers. enero de 2022;14(24):6071.
DOI: 10.3390/cancers14246071
Robinson D, Van Allen EM, Wu YM, Schultz N, Lonigro RJ, Mosquera JM, et al. Integrative Clinical Genomics of Advanced Prostate Cancer. Cell. mayo de 2015;161(5):1215-28.
Seki M, Minamiguchi K, Kajiwara D, Mizutani H, Yoshida S, Sasaki E, et al. TAS3681, a novel type of AR antagonist with AR downregulating activity, as a new targeted therapy for aberrant AR-driven prostate cancer. JCO. 20 de febrero de 2018;36(6_suppl):298-298.
DOI: 10.1200/JCO.2018.36.6_suppl.298
Vogelzang NJ, Levin R, Chu DT, Gabrail NY, Nordquist LT, Stein MN, et al. A phase I/II study of proxalutamide (GT0918), a potent androgen receptor blocker, in patients with mCRPC progressed after both hormonal therapy and chemotherapy. JCO. marzo de 2019;37(7_suppl):169-169.
DOI: 10.1200/JCO.2019.37.7_suppl.169
McMillan EA, Bossard C, Creger E, Merkwirth C, Pippa R, Jarvis M, et al. Abstract 3928: The pan-CLK/DYRK inhibitor cirtuvivint selectively disrupts alternative splicing and has broad anti-tumor activity in preclinical models. Cancer Research. 15 de junio de 2022;82(12_Supplement):3928.
DOI: 10.1158/1538-7445.AM2022-3928
Gao X, Burris III HA, Vuky J, Dreicer R, Sartor AO, Sternberg CN, et al. Phase 1/2 study of ARV-110, an androgen receptor (AR) PROTAC degrader, in metastatic castration-resistant prostate cancer (mCRPC). JCO. 20 de febrero de 2022;40(6_suppl):17-17.
DOI: 10.1200/JCO.2022.40.6_suppl.017
Denmeade SR, Wang H, Agarwal N, Smith DC, Schweizer MT, Stein MN, et al. TRANSFORMER: A Randomized Phase II Study Comparing Bipolar Androgen Therapy Versus Enzalutamide in Asymptomatic Men With Castration-Resistant Metastatic Prostate Cancer. JCO. 20 de abril de 2021;39(12):1371-82.
Jang A, Kendi AT, Sartor O. Status of PSMA-targeted radioligand therapy in prostate cancer: current data and future trials. Ther Adv Med Oncol. enero de 2023;15:175883592311576.
Sartor O, De Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K, et al. Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. N Engl J Med. 16 de septiembre de 2021;385(12):1091-103.
Hofman MS, Emmett L, Sandhu S, Iravani A, Joshua AM, Goh JC, et al. [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. The Lancet. febrero de 2021;397(10276):797-804.
Sartor AO, Morris MJ, Chi KN, De Bono JS, Shore ND, Crosby M, et al. PSMAfore: A phase 3 study to compare 177Lu-PSMA-617 treatment with a change in androgen receptor pathway inhibitor in taxane-naïve patients with metastatic castration-resistant prostate cancer. JCO. 20 de febrero de 2022;40(6_suppl):TPS211-TPS211.
DOI: 10.1200/JCO.2022.40.6_suppl.TPS211
Rebuzzi SE, Rescigno P, Catalano F, Mollica V, Vogl UM, Marandino L, et al. Immune Checkpoint Inhibitors in Advanced Prostate Cancer: Current Data and Future Perspectives. Cancers. 28 de febrero de 2022;14(5):1245.
Sooi K, Walsh R, Kumarakulasinghe N, Wong A, Ngoi N. A review of strategies to overcome immune resistance in the treatment of advanced prostate cancer. Cancer Drug Resist. 25 de septiembre de 2023;6(3):656-73.
Sharma P, Pachynski RK, Narayan V, Fléchon A, Gravis G, Galsky MD, et al. Nivolumab Plus Ipilimumab for Metastatic Castration-Resistant Prostate Cancer: Preliminary Analysis of Patients in the CheckMate 650 Trial. Cancer Cell. octubre de 2020;38(4):489-499.e3.
DOI: 10.1016/j.ccell.2020.08.007
Hotte SJ, Winquist E, Chi KN, Ellard SL, Sridhar S, Emmenegger U, et al. CCTG IND 232: A phase II study of durvalumab with or without tremelimumab in patients with metastatic castration resistant prostate cancer (mCRPC). Annals of Oncology. 1 de octubre de 2019;30:v885.
DOI: 10.1093/annonc/mdz394.044
Powles T, Yuen KC, Gillessen S, Kadel EE, Rathkopf D, Matsubara N, et al. Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: a randomized phase 3 trial. Nat Med. enero de 2022;28(1):144-53.
Hoimes CJ, Graff JN, Tagawa ST, Hwang C, Kilari D, Ten Tije AJ, et al. KEYNOTE-199 cohorts (C) 4 and 5: Phase II study of pembrolizumab (pembro) plus enzalutamide (enza) for enza-resistant metastatic castration-resistant prostate cancer (mCRPC). JCO. 20 de mayo de 2020;38(15_suppl):5543-5543.
DOI: 10.1200/JCO.2020.38.15_suppl.5543
Gratzke C, Kwiatkowski M, De Giorgi U, Martins da Trindade K, De Santis M, Armstrong AJ, et al. KEYNOTE-991: pembrolizumab plus enzalutamide and androgen deprivation for metastatic hormone-sensitive prostate cancer. Future Oncology. diciembre de 2022;18(37):4079-87.
Sridhar SS, Kolinsky MP, Gravis G, Mourey L, Piulats Rodriguez JMM, Romano E, et al. Pembrolizumab (pembro) plus docetaxel and prednisone in patients (pts) with abiraterone acetate (abi) or enzalutamide (enza)-pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort B efficacy, safety and, biomarker results. JCO. 20 de mayo de 2020;38(15_suppl):5550-5550.
DOI: 10.1200/JCO.2020.38.15_suppl.5550
Petrylak DP, Ratta R, Matsubara N, Korbenfeld EP, Gafanov R, Mourey L, et al. Pembrolizumab plus docetaxel for patients with metastatic castration-resistant prostate cancer (mCRPC): Randomized, double-blind, phase 3 KEYNOTE-921 study. JCO. 20 de febrero de 2023;41(6_suppl):19-19.
DOI: 10.1200/JCO.2023.41.6_suppl.19
Corn PG, Heath EI, Zurita A, Ramesh N, Xiao L, Sei E, et al. Cabazitaxel plus carboplatin for the treatment of men with metastatic castration-resistant prostate cancers: a randomised, open-label, phase 1–2 trial. The Lancet Oncology. 1 de octubre de 2019;20(10):1432-43.
Aggarwal R, Starzinski S, Kouchkovsky I de, Koshkin V, Bose R, Chou J, et al. Single-dose 177Lu-PSMA-617 followed by maintenance pembrolizumab in patients with metastatic castration-resistant prostate cancer: an open-label, dose-expansion, phase 1 trial. The Lancet Oncology. 1 de noviembre de 2023;24(11):1266-76.
Sandhu SK, Joshua AM, Emmett L, Spain L, Horvath LG, Crumbaker M, et al. 577O PRINCE: Interim analysis of the phase Ib study of 177Lu-PSMA-617 in combination with pembrolizumab for metastatic castration resistant prostate cancer (mCRPC). Annals of Oncology. 1 de septiembre de 2021;32:S626-7.
DOI: 10.1016/j.annonc.2021.08.1090
Karzai F, VanderWeele D, Madan RA, Owens H, Cordes LM, Hankin A, et al. Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations. j immunotherapy cancer. diciembre de 2018;6(1):141.
Antonarakis ES, Park SH, Goh JC, Shin SJ, Lee JL, Mehra N, et al. Pembrolizumab Plus Olaparib for Patients With Previously Treated and Biomarker-Unselected Metastatic Castration-Resistant Prostate Cancer: The Randomized, Open-Label, Phase III KEYLYNK-010 Trial. JCO. agosto de 2023;41(22):3839-50.
Agarwal N, McGregor B, Maughan BL, Dorff TB, Kelly W, Fang B, et al. Cabozantinib in combination with atezolizumab in patients with metastatic castration-resistant prostate cancer: results from an expansion cohort of a multicentre, open-label, phase 1b trial (COSMIC-021). The Lancet Oncology. 1 de julio de 2022;23(7):899-909.
Agarwal N, Azad A, Carles J, Chowdhury S, McGregor B, Merseburger AS, et al. A phase III, randomized, open-label study (CONTACT-02) of cabozantinib plus atezolizumab versus second novel hormone therapy in patients with metastatic castration-resistant prostate cancer. Future Oncology. marzo de 2022;18(10):1185-98.
Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, et al. Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer. New England Journal of Medicine. 29 de julio de 2010;363(5):411-22.
Madan RA, Mohebtash M, Arlen PM, Vergati M, Rauckhorst M, Steinberg SM, et al. Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. The Lancet Oncology. mayo de 2012;13(5):501-8.
Stein MN, Fong L, Mega AE, Lam ET, Heyburn JW, Gutierrez AA, et al. KEYNOTE-046 (Part B): Effects of ADXS-PSA in combination with pembrolizumab on survival in metastatic, castration-resistant prostate cancer patients with or without prior exposure to docetaxel. JCO. 20 de febrero de 2020;38(6_suppl):126-126.
DOI: 10.1200/JCO.2020.38.6_suppl.126
Hummel HD, Kufer P, Grüllich C, Seggewiss-Bernhardt R, Deschler-Baier B, Chatterjee M, et al. Pasotuxizumab, a BiTE ® immune therapy for castration-resistant prostate cancer: Phase I, dose-escalation study findings. Immunotherapy. febrero de 2021;13(2):125-41.
Tran B, Horvath L, Dorff T, Rettig M, Lolkema MP, Machiels JP, et al. 609O Results from a phase I study of AMG 160, a half-life extended (HLE), PSMA-targeted, bispecific T-cell engager (BiTE®) immune therapy for metastatic castration-resistant prostate cancer (mCRPC). Annals of Oncology. 1 de septiembre de 2020;31:S507.
DOI: 10.1016/j.annonc.2020.08.869
He Y, Xu W, Xiao YT, Huang H, Gu D, Ren S. Targeting signaling pathways in prostate cancer: mechanisms and clinical trials. Signal Transduct Target Ther. 24 de junio de 2022;7(1):198.
Chakravarty D, Johnson A, Sklar J, Lindeman NI, Moore K, Ganesan S, et al. Somatic Genomic Testing in Patients With Metastatic or Advanced Cancer: ASCO Provisional Clinical Opinion. J Clin Oncol. 10 de abril de 2022;40(11):1231-58.
Fraser M, Sabelnykova VY, Yamaguchi TN, Heisler LE, Livingstone J, Huang V, et al. Genomic hallmarks of localized, non-indolent prostate cancer. Nature. 19 de enero de 2017;541(7637):359-64.
Teyssonneau D, Margot H, Cabart M, Anonnay M, Sargos P, Vuong NS, et al. Prostate cancer and PARP inhibitors: progress and challenges. Journal of Hematology & Oncology. 29 de marzo de 2021;14(1):51.
de Bono J, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S, et al. Olaparib for Metastatic Castration-Resistant Prostate Cancer. New England Journal of Medicine. 28 de mayo de 2020;382(22):2091-102.
Agarwal N, Azad AA, Carles J, Fay AP, Matsubara N, Heinrich D, et al. Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial. The Lancet. julio de 2023;402(10398):291-303.
Chi KN, Sandhu S, Smith MR, Attard G, Saad M, Olmos D, et al. Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: second interim analysis of the randomized phase III MAGNITUDE trial. Annals of Oncology. septiembre de 2023;34(9):772-82.
Saad F, Clarke NW, Oya M, Shore N, Procopio G, Guedes JD, et al. Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial. The Lancet Oncology. octubre de 2023;24(10):1094-108.
Fizazi K, Piulats JM, Reaume MN, Ostler P, McDermott R, Gingerich JR, et al. Rucaparib or Physician’s Choice in Metastatic Prostate Cancer. New England Journal of Medicine. 23 de febrero de 2023;388(8):719-32.
Mei L, Zhang J, He K, Zhang J. Ataxia telangiectasia and Rad3-related inhibitors and cancer therapy: where we stand. Journal of Hematology & Oncology. 24 de abril de 2019;12(1):43.
Abel ML, Takahashi N, Peer C, Redon CE, Nichols S, Vilimas R, et al. Targeting Replication Stress and Chemotherapy Resistance with a Combination of Sacituzumab Govitecan and Berzosertib: A Phase I Clinical Trial. Clin Cancer Res. 15 de septiembre de 2023;29(18):3603-11.
Sandhu S, Joshua AM, Emmett L, Crumbaker M, Bressel M, Huynh R, et al. LuPARP: Phase 1 trial of 177Lu-PSMA-617 and olaparib in patients with metastatic castration resistant prostate cancer (mCRPC). JCO. junio de 2023;41(16_suppl):5005-5005.
DOI: 10.1200/JCO.2023.41.16_suppl.5005
Guney Eskiler G, Deveci Ozkan A, Haciefendi A, Bilir C. Mechanisms of abemaciclib, a CDK4/6 inhibitor, induced apoptotic cell death in prostate cancer cells in vitro. Transl Oncol. enero de 2022;15(1):101243.
Sweeney C, Bracarda S, Sternberg CN, Chi KN, Olmos D, Sandhu S, et al. Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial. The Lancet. 10 de julio de 2021;398(10295):131-42.
Número de descargas:
5102
Número de visitas:
296
Citas:
0
